Puma Biotechnology (PBYI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for June 11, 2026, at the company's Los Angeles office.
Holders of record as of April 13, 2026, are entitled to vote on key proposals.
Proxy materials, including the annual report and proxy statement, are available online, with options for paper or email delivery.
Internet-based delivery of proxy materials aims to reduce costs and environmental impact.
Voting matters and shareholder proposals
Election of eight director nominees for a one-year term.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory (non-binding) vote to approve executive compensation.
Approval of an amendment to extend the expiration date of a warrant held by Alan H. Auerbach until October 4, 2028.
Board recommends voting "FOR" all proposals.
Board of directors and corporate governance
Eight nominees listed for election to the board, including Alan H. Auerbach, Alessandra Cesano, Allison Dorval, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson.
Latest events from Puma Biotechnology
- Q1 2026 revenue fell, net loss rose, but debt was repaid and 2026 guidance was raised.PBYI
Q1 20268 May 2026 - NERLYNX revenue grows as Alisertib progresses in phase II trials, with key data expected in 2026.PBYI
TD Cowen 46th Annual Health Care Conference5 May 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and a CEO warrant extension.PBYI
Proxy filing28 Apr 2026 - Annual meeting to vote on directors, auditor, executive pay, and CEO warrant extension.PBYI
Proxy filing7 Apr 2026 - Q4 2025 delivered higher NERLYNX sales, robust royalty growth, and sustained profitability.PBYI
Q4 20254 Apr 2026 - Q2 2024 revenue rose sequentially, net loss narrowed, and FY net income is projected at $12M–$15M.PBYI
Q2 20242 Feb 2026 - Q3 2024 net income surged to $20.3M on $80.5M revenue, with strong China sales and global growth.PBYI
Q3 202415 Jan 2026 - Q4 2024 saw stable NERLYNX sales, higher net income, and a steady 2025 outlook.PBYI
Q4 202426 Dec 2025 - NERLYNX and alisertib advance with stable revenue and key clinical data expected in 2025.PBYI
TD Cowen 45th Annual Healthcare Conference17 Dec 2025